AUDIOCURE-PHARMA-GMBH
High-dose glucocorticoids are no more effective than the standard-dose in treating patients with sudden hearing loss. They are also associated with more side effects and significantly worse outcomes for speech recognition and tinnitus perception. Additionally, 60% of patients treated with the standard dose had not fully recovered by the end of the study. This clinical study, led by Prof. Stefan Plontke from the University Medicine Halle, evaluated the efficacy of different doses of glucocorticoids in over 300 sudden hearing loss patients and is published in NEJM Evidence. These results raise the possibility that glucocorticoids may not be sufficiently effective in treating this condition.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240312579935/en/
Prof. Stefan Plontke, principal investigator of the study at the University Medical Center Halle (Photo: University Medicine Halle).
Sudden hearing loss can drastically impair speech understanding and affect a patient’s daily life. Glucocorticoids are prescribed worldwide as the standard-of-care. However, in certain circumstances their side effects can be severe, and it remains unclear whether they provide meaningful improvement for patients. "These drugs have been used globally for 50 years as the standard of care for sudden hearing loss, still there is no reliable scientific evidence for this practice.", explains study leader Stefan Plontke, underscoring the increasing need for new treatments. Many companies are exploring alternatives. However, there is currently only one clinical trial with a new active substance in which patients can participate: The compound AC102 outperformed the widely used cortisone-like dexamethasone in preclinical models of hearing loss, likely because it specifically targets damaged sensory cells and the auditory nerve. Clinical trials are now testing whether this effect is comparable in humans. "We are not surprised by the HODOKORT study results. Glucocorticoids as anti-inflammatory drugs are a good treatment option for many conditions. However, there is no convincing mode-of-action for the treatment of sudden hearing loss with steroids, as our own research has shown," says Dr. Reimar Schlingensiepen, CEO of AudioCure Pharma.
After 50 years of treating sudden hearing loss with glucocorticoids, a new and effective drug for this condition would represent a much-needed paradigm shift.
Original Study: Plontke, et al. NEJM Evid 2024;3(1) DOI:10.1056/EVIDoa2300172
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312579935/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global tilføjer tilstedeværelse i Fiji med Howards Lawyers18.1.2025 22:23:00 CET | Pressemeddelelse
Andersen Global styrker sin tilstedeværelse i Asien og Stillehavsområdet ved en samarbejdsaftale med det førende kommercielle advokatfirma Howards Lawyers i Republikken Fiji. Howards blev grundlagt i 1986 og ledes af Managing Partner William "Wylie" Clarke. Det er en virksomhed med speciale i turisme, bankvirksomhed og infrastruktur. De betjener multinationale virksomheder, statslige enheder, enkeltpersoner med høj nettoværdi og kunder på tværs af offentlige og private sektorer med omfattende juridiske tjenester og ekspertise inden for ledelse, arbejdsret, kommercielle transaktioner, virksomhedsfinansiering, sikkerhedsdokumentation, inddrivelse af gæld, miljølovgivning , byggeri, luftfart, selskabsret og kontraktret. "Fiji fungerer som indgangsport til det sydlige Stillehav og giver uovertrufne muligheder for konnektivitet med virksomheder, der ekspanderer ind i regionen," siger Wylie. "Som et af Fijis veletablerede advokatfirmaer er vi fortsat forpligtet på at levere enestående kundes
Hero MotoSports Team Rally Secures an Impressive 7th Place Overall Finish at Dakar Rally 202517.1.2025 21:31:00 CET | Press release
The Indian Manufacturer Team’s Second-Best Dakar Performance in Nine Years Hero MotoSports Team Rally, the motorsport team of the world’s largest manufacturer of motorcycles and scooters - Hero MotoCorp, has successfully completed the Dakar Rally 2025, reinforcing its position as a formidable force in the world’s toughest rally. The team completed this year’s rally at overall 7th position, registering its second best Dakar performance in nine years, after it finished 2nd overall at the world’s toughest rally last year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250117472643/en/ Hero MotoSports at Dakar Rally Stage 12 (Photo: Business Wire) The team’s young Chilean rider, Nacho Cornejo, delivered a stellar performance, maintaining top-10 standings throughout the rally and securing an overall 7th place finish. Nacho showcased remarkable grit and determination, demonstrating his consistency across the stages. Since Stage 1,
Qualcomm Announces Quarterly Cash Dividend17.1.2025 15:00:00 CET | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.85 per common share, payable on March 27, 2025, to stockholders of record at the close of business on March 6, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Our proven solutions drive transformation across major industries, and our Snapdragon® branded platforms power extraordinary consumer experiences. Building on our nearly 40-year leadership in setting industry standards and creating era-defining technology breakthroughs, we deliver leading edge AI, high-performance, low-power computing, and unrivaled connectivity. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business, QTL, and the vast majority
Jefferies Clients, Shareholders and Employees Contribute $10 Million to Charities Supporting Los Angeles Wildfire Relief17.1.2025 14:00:00 CET | Press release
Jefferies announced today that it will donate $10 million to charities providing aid for first responders and the people and communities impacted by the wildfires across Los Angeles. The donation includes funds from Jefferies, voluntary contributions from its nearly 6,000 worldwide employees, and proceeds from the firm’s January 16 Doing Good Global Trading Day, which set aside 100% of net global trading commissions for charities. Rich Handler, CEO, and Brian Friedman, President of Jefferies, said: “We are so grateful for how the Jefferies network stepped up to support those in need in Los Angeles. These wildfires have inflicted heartbreaking devastation on communities and so many families, and we hope this donation will help deserving charities provide urgently needed relief.” Organization Charity Description Allocation Los Angeles Fire Department Foundation The LAFD is actively seeking funds to equip LAFD members battling wildfires with tools and supplies. $2,000,000 All Hands and He
SLB Announces Fourth-Quarter and Full-Year 2024 Results, Increases Dividend and Initiates $2.3 billion in Accelerated Share Repurchases17.1.2025 12:50:00 CET | Press release
Fourth-quarter revenue of $9.28 billion increased 1% sequentially and 3% year on year Fourth-quarter GAAP EPS of $0.77 decreased 7% sequentially but was flat year on year Fourth-quarter EPS, excluding charges and credits, of $0.92 increased 3% sequentially and 7% year on year Fourth-quarter net income attributable to SLB of $1.10 billion decreased 8% sequentially and 2% year on year Fourth-quarter adjusted EBITDA of $2.38 billion increased 2% sequentially and 5% year on year Fourth-quarter cash flow from operations was $2.39 billion and free cash flow was $1.63 billion Board approved a 3.6% increase in quarterly cash dividend to $0.285 per share Full-year revenue of $36.29 billion increased 10% year on year Full-year GAAP EPS of $3.11 increased 7% year on year Full-year EPS, excluding charges and credits, of $3.41 increased 14% year on year Full-year net income attributable to SLB of $4.46 billion increased 6% year on year Full-year adjusted EBITDA of $9.07 billion increased 12% year o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom